Frank Borriello, MD, PhD, on Promising Activity of SUPLEXA-101 Across Cancers

The scientific cofounder and chief executive officer of Alloplex Biotherapeutics discussed early data from a phase 1 trial of the PBMC-derived therapy.

“So far, the results have been very interesting... I'm very happy to report that we have 0 drug-related adverse events...the second thing that we noticed is that many of the patients that are in our trial [with] 12 cancers represented in the first 25 patients... at the first measurement, after starting to receive our therapy, the tumors stabilize. They don’t continue to grow. And this is just after 3 doses of our weekly therapy."

SUPLEXA-101, a peripheral blood mononuclear cell (PBMC)-derived activated white blood cell therapy comprised predominantly of natural killer (NK) cells, natural killer T (NKT) cells, γδ T cells, and cytotoxic CD8-positive and CD4-positive T lymphocytes αβ T cells, has demonstrated an excellent safety profile and promising clinical activity across solid and liquid tumor types.

Data from the phase 1 trial (NCT05237206) evaluating SUPLEXA-101 were presented at the World Oncology Cell Therapy Congress (WOCTC) held April 25-26 in Boston, Massachusetts, by Frank Borriello, MD, PhD, scientific cofounder and chief executive officer, Alloplex Biotherapeutics. CGTLive spoke with Borriello to learn more about SUPLEXA-101 and the potential advantages that it may offer across different cancers.

Borriello discussed the manufacturing, cost, and accessibility advantages that the cell therapy offers due to it being a target-agnostic therapy. He also discussed the pharmacodynamics observed in the first treated patients, including white blood cell profiles in these patients being corrected toward normal levels within 2 weeks of administration and a marked decrease in myeloid-derived suppressor cells which are correlated with patient responses. He also hypothesized that using SUPLEXA-101 in combination with other treatment strategies, such as checkpoint inhibitors, may yield more durable and efficacious responses in treating cancers.

Borriello, F. Preliminary First-in-Human Data from an Exploratory Clinical Trial of SUPLEXA Therapeutic Cells. Presented at: WOCTC; April 25-26; Boston, Massachusetts.
Related Videos
Binod Dhakal, MD, on Assessing Cilta-Cel in Lenalidomide-Refractory Multiple Myeloma
Brian Van Tine, MD, PhD, on Further Research With Cell Therapy in Synovial Sarcoma
Brian Van Tine, MD, PhD, on Continued Durability of Afami-Cel in Synovial Sarcoma
Thomas McCauley, PhD, on Treating Solid Tumors With Epigenomic Controllers
Rebecca Cottman, PhD, on Creating Regulated Gene Circuits to Enhance Cell Therapy Cytotoxicity
John Leonard, PhD, on an AAV Approach to Exon 51 Skipping in DMD
Joseph Fraietta, PhD, on Investigating Molecular Pathways of CAR T-Cell Resistance
Related Content
© 2023 MJH Life Sciences

All rights reserved.